ELV — overbought is a timing input, not a reversal call. Trends in this configuration have historically resumed after short consolidation phases; the 200-day average (~$324) is a natural reversion reference.
Elevance Health, Inc. trades in bullish territory at $344.76, 6.3% above its 200-day moving average, yet the composite score of 1.0/10 flags caution. Surface trend stays positive; deeper indicators diverge — a pattern that has historically preceded pullbacks in the Healthcare sector.
20-day ATR on ELV is in the middle band (beta 0.50). Paired with a bull regime, this produces the kind of steady-state tape where standard 30–45 DTE cycles have historically behaved consistently.
ELV's price momentum is accelerating — the rate of change is increasing rather than flattening. At $344.76, 6.3% above the 200-day average, the tape shows the kind of impulse that has historically persisted for multiple weeks in the Healthcare sector.
ELV registers overbought on oscillator-based measures. Historically, overbought conditions in uptrends have preceded short consolidation phases rather than full reversals, but the 200-day average (~$324) is a natural reversion reference.
Cash-secured puts require holding cash equal to strike × 100 shares as collateral. Strike defaults to ~5% OTM, snapped to typical exchange increments. Premium defaults to ~2% of strike — adjust to your real expected fill. Annualized ROC = (premium ÷ collateral) × (365 ÷ DTE). CSP risk is single-name concentration: experienced put-sellers typically diversify across 4–6 underlyings rather than committing the whole account to one ticker. Continuous-rolling projections assume capital can be re-deployed after each expiration and that comparable premiums remain available — actual results vary with market conditions, assignments, and rolls.